journal
https://read.qxmd.com/read/38749880/reply-to-marco-moschini-francesco-montorsi-giuseppe-rosiello-andrea-salonia-and-alberto-briganti-s-letter-to-the-editor-re-stamatios-katsimperis-lazaros-tzelves-zafer-tandogdu-et-al-complications-after-radical-cystectomy-a-systematic-review-and-meta-analysis
#1
LETTER
Stamatios Katsimperis, Lazaros Tzelves, Zafer Tandogdu, Anthony Ta, Robert Geraghty, Themistoklis Bellos, Ioannis Manolitsis, Nikolaos Pyrgidis, Gerald Bastian Schulz, Ashwin Sridhar, Gregory Shaw, John Kelly, Andreas Skolarikos
No abstract text is available yet for this article.
May 14, 2024: European Urology Focus
https://read.qxmd.com/read/38749879/oncological-and-functional-outcomes-of-penile-shaft-sparing-surgery-for-localised-penile-cancer-a-systematic-review
#2
REVIEW
Giuseppe Fallara, Giuseppe Basile, Adrian Poterek, Marco Tozzi, Karl H Pang, Omer Onur Çakir, Marco Bandini, Matteo Ferro, Gennaro Musi, Maria Satchi, Angelo Territo, Christian Fankhauser, Fabio Castiglione
CONTEXT: Penile shaft sparing (PSS) surgery for localised penile cancer (PeCa) aims to balance oncological and functional outcomes. OBJECTIVE: To summarise the published evidence on different PSS approaches. EVIDENCE ACQUISITION: We performed a systematic review adhering to Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. The systematic search was performed on PubMed, EMBASE, and Scopus databases up to February 14, 2023...
May 14, 2024: European Urology Focus
https://read.qxmd.com/read/38744565/clinical-practice-guide-management-of-chylous-ascites-after-retroperitoneal-lymph-node-dissection
#3
JOURNAL ARTICLE
Kenneth Chen, John Thng, Darren Ho, Nathan Lawrentschuk
Chylous ascites is a rare but challenging complication after retroperitoneal lymph node dissection. Conservative management is successful in most cases, with percutaneous lymphangiography reserved for refractory instances. Surgical interventions are associated with high failure rates.
May 13, 2024: European Urology Focus
https://read.qxmd.com/read/38729824/serum-levels-of-microrna-371a-3p-for-predicting-the-histology-of-postchemotherapy-residual-masses-of-germ-cell-tumours
#4
JOURNAL ARTICLE
Klaus-Peter Dieckmann, Francesca Grobelny, Armin Soave, Yue Che, Tim Nestler, Cord Matthies, Julia Heinzelbecker, Alexander Winter, Axel Heidenreich, Tabea Niemzok, Cansu Dumlupinar, Markus Angerer, Christian Wülfing, Pia Paffenholz, Gazanfer Belge
BACKGROUND AND OBJECTIVE: Serum levels of microRNA-371a-3p (M371) represent a novel and sensitive biomarker of germ cell tumours (GCTs). This study analysed the utility of M371 to identify viable cancer (VC) in postchemotherapy (pc) residual masses with the underlying goal of avoiding overtreatment. METHODS: A multicentric, prospective diagnostic study was conducted in 180 GCT patients undergoing pc resection of residual masses. A correlation of M371 measurement results with the histological presence of VC in masses was found...
May 9, 2024: European Urology Focus
https://read.qxmd.com/read/38724341/overview-of-novel-biomarkers-for-management-of-postchemotherapy-residual-masses-in-testicular-cancer
#5
JOURNAL ARTICLE
Renjie Ding, Xiangdong Li, Zhuowei Liu
The diagnosis of postchemotherapy residual masses in testicular cancer must be based on the integration of clinical, imaging, and serology tests. Further validation is needed for novel biomarkers.
May 8, 2024: European Urology Focus
https://read.qxmd.com/read/38692949/association-of-5%C3%AE-reductase-inhibitors-with-depression-and-suicide-a-mini-systematic-review-and-meta-analysis
#6
REVIEW
Alessandro Uleri, Jean Nicolas Cornu, Andrea Gobbo, Thomas R W Herrmann, Cosimo De Nunzio, Hashim Hashim, Michael Baboudjian
5α-Reductase inhibitors (5-ARIs) are widely prescribed for treatment of benign prostatic obstruction and androgenic alopecia. Several studies with controversial findings regarding 5-ARI exposure have been published over a number of years, and concerns were recently raised about the potential risks of depression and suicide associated with 5-ARIs. To investigate this association, we conducted a systematic review of the literature and a meta-analysis. Five studies involving 2213600 patients met our inclusion criteria...
April 30, 2024: European Urology Focus
https://read.qxmd.com/read/38688825/diagnostic-utility-of-artificial-intelligence-assisted-transperineal-biopsy-planning-in-prostate-cancer-suspected-men-a-prospective-cohort-study
#7
JOURNAL ARTICLE
Karsten Guenzel, Georg Lukas Baumgaertner, Anwar R Padhani, Johannes Luckau, Uwe Carsten Lock, Tomasz Ozimek, Stefan Heinrich, Jakob Schlegel, Jonas Busch, Ahmed Magheli, Julian Struck, Hendrik Borgmann, Tobias Penzkofer, Bernd Hamm, Stefan Hinz, Charlie Alexander Hamm
BACKGROUND AND OBJECTIVE: Accurate magnetic resonance imaging (MRI) reporting is essential for transperineal prostate biopsy (TPB) planning. Although approved computer-aided diagnosis (CAD) tools may assist urologists in this task, evidence of improved clinically significant prostate cancer (csPCa) detection is lacking. Therefore, we aimed to document the diagnostic utility of using Prostate Imaging Reporting and Data System (PI-RADS) and CAD for biopsy planning compared with PI-RADS alone...
April 29, 2024: European Urology Focus
https://read.qxmd.com/read/38677913/comparative-effectiveness-of-partial-gland-cryoablation-versus-robotic-radical-prostatectomy-for-cancer-control
#8
JOURNAL ARTICLE
Alec Zhu, Mary O Strasser, Timothy D McClure, Sofia Gereta, Emily Cheng, Kshitij Pandit, Jim C Hu
BACKGROUND AND OBJECTIVE: There is an absence of high-level evidence comparing oncologic endpoints for partial gland ablation, and most series use prostate-specific antigen (PSA) rather than biopsy endpoints. Our aim was to compare oncologic outcomes between partial gland cryoablation (PGC) and radical prostatectomy (RP) for prostate cancer. METHODS: This was a retrospective, single-center analysis of subjects treated with PGC (n = 98) or RP (n = 536) between January 2017 and December 2022 as primary treatment for intermediate-risk (Gleason grade group [GG] 2-3) prostate cancer...
April 26, 2024: European Urology Focus
https://read.qxmd.com/read/38670842/benign-prostatic-hyperplasia-surgery-a-snapshot-of-trends-costs-and-surgical-retreatment-rates-in-the-usa
#9
JOURNAL ARTICLE
Francesco Ditonno, Celeste Manfredi, Leslie Claire Licari, Eugenio Bologna, Antonio Franco, Savio D Pandolfo, Marco De Sio, Cosimo De Nunzio, Cristian Fiori, Edward E Cherullo, Ephrem O Olweny, Alessandro Antonelli, Riccardo Autorino
BACKGROUND: An increasing number of novel surgical treatments (NSTs) for benign prostatic hyperplasia (BPH) have been proposed over time to achieve similar functional outcomes, but better perioperative and sexual outcomes than traditional procedures. OBJECTIVE: To assess the trends in the utilization and costs of BPH surgical procedures over the past decade, and to analyze the need for surgical retreatment after each procedure. DESIGN, SETTING, AND PARTICIPANTS: A retrospective observational population-based analysis was conducted using the PearlDiver Mariner (PearlDiver Technologies, Colorado Springs, CO, USA) database, including all-payer nationally available claims records collected from 2011 to 2022...
April 25, 2024: European Urology Focus
https://read.qxmd.com/read/38670841/re-steven-monda-manolis-pratsinis-hansen-lui-et-al-secondary-bladder-cancer-after-prostate-cancer-treatment-an-age-matched-comparison-between-radiation-and-surgery-eur-urol-focus-in-press-http-doi-org-10-1016-j-euf-2023-09-002
#10
LETTER
https://read.qxmd.com/read/38658299/the-future-of-front-line-metastatic-bladder-cancer-is-platinum-free
#11
JOURNAL ARTICLE
Matthew Young
Management of metastatic bladder cancer has historically been challenging. However, enfortumab vedotin plus pembrolizumab (EV/P) has recently been accepted as a new standard of care, replacing platinum-based chemotherapy, because of improvements in survival and response rates. The benefits of the EV/P combination and some of the questions that arise in this new treatment landscape are discussed.
April 23, 2024: European Urology Focus
https://read.qxmd.com/read/38644097/bacterial-vaccines-for-the-management-of-recurrent-urinary-tract-infections-a-systematic-review-and-meta-analysis
#12
REVIEW
Quentin Mak, Julian Greig, Prokar Dasgupta, Sachin Malde, Nicholas Raison
BACKGROUND AND OBJECTIVE: Several bacterial immunisations have been developed to reduce the socioeconomic burden of urinary tract infections (UTIs) and the use of prophylactic antibiotics in the management of recurrent UTIs (rUTIs). This systematic review evaluates the effectiveness of vaccinations in preventing rUTIs. METHODS: Medline, Embase, and Web of Science were searched from inception to December 2023. Data were collected from cohort studies with a comparator arm and randomised controlled trials (RCTs) investigating vaccination efficacy in adult rUTI patients according to predefined selection criteria (PROSPERO registration: CRD42022356662)...
April 20, 2024: European Urology Focus
https://read.qxmd.com/read/38631992/a-systematic-review-on-the-impact-of-quality-assurance-programs-on-outcomes-after-radical-prostatectomy
#13
REVIEW
Sophia H van der Graaf, Marinus J Hagens, Hans Veerman, Ton A Roeleveld, Jakko A Nieuwenhuijzen, Esther M K Wit, Michel W J M Wouters, Stevie van der Mierden, R Jeroen A van Moorselaar, Harrie P Beerlage, André N Vis, Pim J van Leeuwen, Henk G van der Poel
BACKGROUND AND OBJECTIVE: The implementation of quality assurance programs (QAPs) within urological practice has gained prominence; yet, their impact on outcomes after radical prostatectomy (RP) remains uncertain. This paper aims to systematically review the current literature regarding the implementation of QAPs and their impact on outcomes after robot-assisted RP, laparoscopic RP, and open prostatectomy, collectively referred to as RP. METHODS: A systematic Embase, Medline (OvidSP), and Scopus search was conducted, according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) process, on January 12, 2024...
April 16, 2024: European Urology Focus
https://read.qxmd.com/read/38631991/biomarkers-of-response-to-anti-nectin4-antibody-drug-conjugate-enfortumab-vedotin-in-urothelial-cancer
#14
REVIEW
Niklas Klümper, Markus Eckstein
Initial studies indicated that NECTIN4 expression is widespread in metastatic urothelial cancer (mUC), which led to approval of the anti-NECTIN4 antibody-drug conjugate (ADC) enfortumab vedotin (EV) for unselected patients with mUC. However, the recent literature suggests that there has been overestimation of membranous NECTIN4 expression in UC, which is a prerequisite for EV binding. It is well established from the development of Her2-targeting ADCs that treatment response is strongly dependent on membranous expression level of the relevant target antigen...
April 16, 2024: European Urology Focus
https://read.qxmd.com/read/38627124/results-at-1-year-from-saturn-a-european-prospective-multicenter-registry-for-male-stress-urinary-incontinence-surgery
#15
JOURNAL ARTICLE
John Heesakkers, Frank Martens, Nikesh Thiruchelvam, Wim Witjes, Christien Caris, Joni Kats, Rizwan Hamid, Frank Van der Aa
BACKGROUND AND OBJECTIVE: The European, prospective, multicenter SATURN registry was developed to analyze surgical devices for male stress urinary incontinence. The primary objective is the cure rate during follow-up. METHODS: Efficacy, complications, patient-reported outcomes, and prognostic factors are being analyzed at various intervals during 10-yr follow-up. The results at 1-yr follow-up are presented here. KEY FINDINGS AND LIMITATIONS: The cohort included 1046 patients (mean age 70 yr) from 28 centers in nine countries...
April 15, 2024: European Urology Focus
https://read.qxmd.com/read/38600021/promoting-green-in-person-scientific-conferences
#16
LETTER
Pietro Diana, Benjamin Pradere, Alessandro Uleri, Michael Baboudjian
No abstract text is available yet for this article.
April 9, 2024: European Urology Focus
https://read.qxmd.com/read/38582643/front-line-platinum-continues-to-have-a-role-in-advanced-bladder-cancer
#17
JOURNAL ARTICLE
Ursula M Vogl, Irene Testi, Maria De Santis
Cisplatin remains a valid option in muscle-invasive or metastatic urothelial carcinoma, and is even more efficient when nivolumab is added. The well-known side-effect profile and the limited number of treatment cycles represent great advantages over modern drug combinations such as enfortumab-vedotin plus pembrolizumab.
April 5, 2024: European Urology Focus
https://read.qxmd.com/read/38582642/re-narek-shaverdian-and-reshma-jagsi-when-headlines-harm-patients-with-cancer-jama-oncol-2023-9-1611-2
#18
LETTER
Francesco Montorsi, Marco Moschini, Mario de Angelis, Alberto Briganti, Andrea Gallina, Nazareno Suardi, Federico Dehò
No abstract text is available yet for this article.
April 5, 2024: European Urology Focus
https://read.qxmd.com/read/38580524/impact-of-synchronous-versus-metachronous-metastasis-on-outcomes-in-patients-with-metastatic-renal-cell-carcinoma-treated-with-first-line-immune-checkpoint-inhibitor-based-combinations
#19
JOURNAL ARTICLE
Georges Gebrael, Luis Meza, Xiaochen Li, Zeynep Zengin, Nicolas Sayegh, Hedyeh Ebrahimi, Nishita Tripathi, Daniela Castro, Benjamin Mercier, Regina Barragan-Carrillo, Haoran Li, Alexander Chehrazi-Raffle, Umang Swami, Abhishek Tripathi, Neeraj Agarwal, Benjamin L Maughan, Sumanta K Pal
BACKGROUND AND OBJECTIVE: The impact of time of metastasis onset with respect toprimary renal cell carcinoma (RCC) diagnosis on survival outcomes is not well characterized in the era of immune checkpoint inhibitor (ICI)-based combinations. Herein, we assessed differences in clinical outcomes between synchronous and metachronous metastatic RCC (mRCC). METHODS: Data for patients with mRCC treated with first-line ICI-based combination therapies between 2014 and 2023 were retrospectively collected...
April 4, 2024: European Urology Focus
https://read.qxmd.com/read/38531756/prostatic-artery-embolisation-versus-transurethral-resection-of-the-prostate-for-benign-prostatic-obstruction-5-year-outcomes-of-a-randomised-open-label-noninferiority-trial
#20
JOURNAL ARTICLE
Gautier Müllhaupt, Lukas Hechelhammer, Nicole Graf, Livio Mordasini, Hans-Peter Schmid, Daniel S Engeler, Dominik Abt
BACKGROUND AND OBJECTIVE: Prostatic artery embolisation (PAE) and transurethral resection of the prostate (TURP) are two of the surgical options for treatment of lower urinary tract symptoms/benign prostatic obstruction (LUTS/BPO). Our aim was to compare the efficacy and safety of PAE and TURP for LUTS/BPO treatment at long-term follow-up. METHODS: We conducted a randomised, open-label, single-centre trial at a Swiss tertiary care centre. The main outcome was the change in International Prostate Symptom Score (IPSS) after PAE versus TURP...
March 25, 2024: European Urology Focus
journal
journal
52364
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.